In the design of novel, highly efficacious and highly sensitive cell therapies, current methods to evaluate the impact of varying antigen density are limiting. Genetic methods to modify surface antigen expression on target cells has been commonplace, but these methods rely on producing and culturing many cell lines that can diverge over time. MatchBio’s CombiCell platform provides a new state of the art solution which transforms our ability to study cell-cell interactions and generate better therapeutics.